Highlights Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:31:30 06/03/2026 GMT			5-day change	1st Jan Change
123.26 ^CHF	-1.25%		-3.78%	+12.46%

03:26pm	Novartis Shareholders Approve Dividend Raise, Share Capital Reduction	MT
02:21pm	Novartis AG Approves Board and Committee Appointments	CI

Highlights

03:26pm	Novartis Shareholders Approve Dividend Raise, Share Capital Reduction	MT
02:21pm	Novartis AG Approves Dividend for 2025, Payable from March 12, 2026	CI
02:20pm	Servier to buy Day One Biopharma for $2.5 billion in tumor treatment push	RE
03-05	FTSE 100 to rise, Reckitt celebrates "strong year"	AN
03-04	Citius Oncology, Inc. Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR Dosing Prior to Commercial CAR-T Therapy in High-Risk Diffuse Large B-Cell Lymphoma	CI
02-27	Sector Update: Health Care Stocks Advance Late Afternoon	MT
02-27	Tariffs Influenced Novartis to Build Over 7 Plants in US, Trump Says	MT
02-27	Novartis AG completed the acquisition of Avidity Biosciences, Inc. from RTW Biotech Opportunities Ltd and others.	CI
02-27	European Stocks Mostly Higher in Friday Trading; French GDP Growth Slows, Inflation Rises	MT
02-27	Atrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates	MT
02-27	Novartis Completes Acquisition of Avidity Biosciences	MT
02-27	Novartis Closes $12 Billion Acquisition of Avidity Biosciences	MT
02-27	Novartis Closes $12 Billion Acquisition of Avidity Biosciences	MT
02-27	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid Inflation Data Release	MT
02-27	Novartis completes acquisition of Avidity Biosciences	RE
02-27	Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy	DJ
02-27	Novartis Says EMA Panel Recommends Remibrutinib for Chronic Spontaneous Urticaria	MT
02-27	Novartis Receives Positive Chmp Opinion for Remibrutinib in Chronic Spontaneous Urticaria	CI
02-27	Novartis' Urticaria Receives Positive Opinion from European Medicines Agency Agency	MT
02-25	European Stocks Mostly Higher in Wednesday Trading; EU, Euro Area Inflation Declines in January	MT
02-25	Novartis to Build New Radioligand Therapy Site in Denton, Texas, Delivering More Next-Generation Treatment to Patients	CI
02-25	Novartis AG to Build Radioligand Therapy Manufacturing Site in Texas, Expand US network	MT
02-25	Novartis to Build Radioligand Therapy Manufacturing Site in Texas, US	MT
02-24	Novartis Settles Lawsuit Over Use of HeLa Cells	MT
02-24	Novartis Announces Multiple US Real-World Studies Delivering New Insights Across Metastatic Prostate Cancer	CI